Chelation Therapy (page 2)
The peer-reviewed protocol from Rozema approved by the American Board of Chelation Therapy
and the International Board of Chelation Therapy, involves intravenous infusion of an osmotically
standardized EDTA solution over 1.5-3.0 hours. Frequency of treatment is usually once or twice
a week; for symptomatic patients a series of 30 or more infusions may be indicated. As
documented by Rozema, EDTA chelation therapy benefits all forms of atherosclerotic occlusive
arterial disease.
Other disease processes have also been found to benefit from chelation. Scleroderma patients
have experienced marked improvement, although lack of benefit was also reported. Rozema
claims, “diabetics usually demonstrate great improvement...insulin or oral hypoglycemic
medications for glucose control can be reduced or eliminated altogether.” Case histories indicate
benefit in Alzheimer’s disease, multiple sclerosis, rheumatoid arthritis, porphyrias, hypertension,
calcinosis universalis and other calcium deposition diseases. Visual function in macular
degeneration cases is also often improved.
and the International Board of Chelation Therapy, involves intravenous infusion of an osmotically
standardized EDTA solution over 1.5-3.0 hours. Frequency of treatment is usually once or twice
a week; for symptomatic patients a series of 30 or more infusions may be indicated. As
documented by Rozema, EDTA chelation therapy benefits all forms of atherosclerotic occlusive
arterial disease.
Other disease processes have also been found to benefit from chelation. Scleroderma patients
have experienced marked improvement, although lack of benefit was also reported. Rozema
claims, “diabetics usually demonstrate great improvement...insulin or oral hypoglycemic
medications for glucose control can be reduced or eliminated altogether.” Case histories indicate
benefit in Alzheimer’s disease, multiple sclerosis, rheumatoid arthritis, porphyrias, hypertension,
calcinosis universalis and other calcium deposition diseases. Visual function in macular
degeneration cases is also often improved.
| Copyright © 2003-2004 Boulder Natural Medicine Clinic, LLC. All rights reserved. Email : info@bouldernatural.com Phone: 303.447.1339 |
| Boulder Natural Medicine Clinic, LLC |
 |
| |
 |
| |
 |
| |
 |
 | |  | |  | |  | |  | |  |
Rozema has thoroughly documented the pharmacology and safety of
EDTA. Gordon and Vance and Halstead earlier reviewed possible
mechanisms for its cardiovascular efficacy, yet no distinct mechanism has
been established for the cardiotonic benefits from EDTA. Absolute
contraindications for EDTA therapy are limited to rare patients exhibiting
chemical intolerance to EDTA, patients with acute lead encephalopathy, or
patients on renal dialysis. Renal damage is estimated to occur in less than
1 in 30,000 patients, and then only in those with pre-existing kidney hypo
function. EDTA chelation is not yet proven safe for women who are
pregnant or might become pregnant.
EDTA. Gordon and Vance and Halstead earlier reviewed possible
mechanisms for its cardiovascular efficacy, yet no distinct mechanism has
been established for the cardiotonic benefits from EDTA. Absolute
contraindications for EDTA therapy are limited to rare patients exhibiting
chemical intolerance to EDTA, patients with acute lead encephalopathy, or
patients on renal dialysis. Renal damage is estimated to occur in less than
1 in 30,000 patients, and then only in those with pre-existing kidney hypo
function. EDTA chelation is not yet proven safe for women who are
pregnant or might become pregnant.
